FDA Epitalon briefing document US Food and Drug Administration
15 Amino acid peptide sequence derived from body protective compound Multi Tissue healing supportgut, tendons, ligaments, muscles, and more Questions BPC-157 is administered via subcutaneous injection into the fatty tissue beneath the skin, or in some cases, intramuscularly near the injury site
Lyophilized peptides are generally more stable than peptide solutions, as theyve been freeze-dried, which means the water has been removed
Improves support, adherence, home exercise compliance, and lifestyle change adoption Observations from practice (Chiromed, LinkedIn): Patients improve when they understand thewh behind care Rehabilitation adheres when connected to meaningful life goals Adjustments paired with active motor correction yield fewer flare-ups Sleep and protein sufficiency correlate with faster tendon recovery Imaging guides safety, but the exam drives care decisions Clear education reduces fear-avoidance and delays References: Evidence-based medicine: What it is and what it isnt (Sackett et al., 1996) Non-invasive treatments for low back pain guideline (Qaseem et al., 2017) Neck pain CPG revision 2017 (Blanpied et al., 2017) Manual therapy mechanisms (Bialosky et al., 2018) Rehabilitation Milestones and Outcome Measurement Stages: Relief and protection Isometrics reduce tendon pain
Translational Gap: None for the mechanism itself
Generally well-tolerated in research settings Mild nausea with higher doses Injection site redness or discomfort Rare: Dizziness or lightheadedness Potential effect on blood pressure (monitor if hypertensive) BPC-157 (Oral) is banned from 503A compounding pharmacies
